Skip to main content
SpringerLink
Log in

TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Mantle cell lymphoma (MCL) is incurable in most patients. Several molecular markers have been identified as possible prognostic factors in MCL, including TP53 mutations. Direct sequencing was used to detect 32 cases with leukemic presentation of MCL form exons 2–11 in order to explore the prognostic significance of TP53 mutations in Chinese patients. Within the MCL cohort, 6(18.8%) patients harbored TP53 mutations. TP53 mutations in the absence of del(17p13) were found in 5.0% of MCL cases (1 of 20) compared with 83.3% of MCL cases (5 of 6) with del(17p13). Compared with patients without TP53 mutations, TP53 mutations were associated with risk factors including age, higher serum lactate dehydrogenase, lymphocytosis, high-risk (HR) international prognostic index, HR mantle cell lymphoma international prognostic index, complex karyotype, and higher occurrence of TP53 deletions. In contrast, it is found that TP53 mutations were correlated with mutated immunoglobulin heavy-chain variable region status and CD38 negative. TP53 mutations were the significant factors in predicting survival in univariate analysis, but unfortunately they were not the unique variable associated with overall survival by multivariate Cox regression analysis. TP53 mutation was insufficiently an independent prognostic factor in patients with MCL at advanced stage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009;27:511–8.

    Article  PubMed  Google Scholar 

  2. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7:750–62.

    Article  PubMed  CAS  Google Scholar 

  3. Salaverria I, Perez-Galan P, Colomer D, Campo E. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica. 2006;91:11–6.

    PubMed  CAS  Google Scholar 

  4. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558–65.

    Article  PubMed  CAS  Google Scholar 

  5. Hartmann EM, Ott G, Rosenwald A. Molecular outcome prediction in mantle cell lymphoma. Future Oncol. 2009;5:63–73.

    Article  PubMed  CAS  Google Scholar 

  6. Tabe Y, Sebasigari D, Jin L, et al. MDM2 antagonist nutlin-3 displays antiproliferative and proapoptotic activity in mantle cell lymphoma. Clin Cancer Res. 2009;15:933–42.

    Article  PubMed  CAS  Google Scholar 

  7. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000;77:81–137.

    Article  PubMed  CAS  Google Scholar 

  8. Greiner TC, Dasgupta C, Ho VV, et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci USA. 2006;103:2352–7.

    Article  PubMed  CAS  Google Scholar 

  9. Swerdlow SH, Campo E, Seto M. Muller-Hermelink: mantle cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. p. 229–32.

    Google Scholar 

  10. Katzenberger T, Kienle D, Stilgenbauer S, et al. Delineation of distinct tumour profiles in mantle cell lymphoma by detailed cytogenetic, interphase genetic and morphological analysis. Br J Haematol. 2008;142:538–50.

    Article  PubMed  Google Scholar 

  11. Xu W, Li JY, Wu YJ, et al. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. Leuk Res. 2008;32:1071–7.

    Article  PubMed  CAS  Google Scholar 

  12. Dong HJ, Zhou LT, Zhu DX, et al. The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13). Ann Hematol. 2011;90:709–17.

    Article  PubMed  CAS  Google Scholar 

  13. Dicker F, Herholz H, Schnittger S, et al. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia. 2009;23:117–24.

    Article  PubMed  CAS  Google Scholar 

  14. Fernandez V, Hartmann E, Ott G, Campo E, Rosenwald A. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways. J Clin Oncol. 2005;23:6364–9.

    Article  PubMed  CAS  Google Scholar 

  15. Espinet B, Salaverria I, Bea S, et al. Incidence and prognostic impact of secondary cytogenetic aberrations in a series of 145 patients with mantle cell lymphoma. Genes Chromosomes Cancer. 2010;49:439–51.

    PubMed  CAS  Google Scholar 

  16. Chipuk JE, Green DR. Dissecting p53-dependent apoptosis. Cell Death Differ. 2006;13:994–1002.

    Article  PubMed  CAS  Google Scholar 

  17. Greiner TC, Moynihan MJ, Chan WC, et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood. 1996;87:4302–10.

    PubMed  CAS  Google Scholar 

  18. Stefancikova L, Moulis M, Fabian P, et al. Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma. Int J Oncol. 2010;36:699–706.

    PubMed  CAS  Google Scholar 

  19. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2003;349:2042–54.

    Article  PubMed  CAS  Google Scholar 

  20. Malcikova J, Smardova J, Pekova S, et al. Identification of somatic hypermutations in the TP53 gene in B-cell chronic lymphocytic leukemia. Mol Immunol. 2008;45:1525–9.

    Article  PubMed  CAS  Google Scholar 

  21. Solenthaler M, Matutes E, Brito-Babapulle V, Morilla R, Catovsky D. p53 and mdm2 in mantle cell lymphoma in leukemic phase. Haematologica. 2002;87:1141–50.

    PubMed  CAS  Google Scholar 

  22. Pileri SA, Falini B. Mantle cell lymphoma. Haematologica. 2009;94:1488–92.

    Article  PubMed  CAS  Google Scholar 

  23. Obrador-Hevia A, Fernandez de Mattos S, Villalonga P, Rodriguez J. Molecular biology of mantle cell lymphoma: from profiling studies to new therapeutic strategies. Blood Rev. 2009;23:205–16.

    Article  PubMed  CAS  Google Scholar 

  24. Thelander EF, Rosenquist R. Molecular genetic characterization reveals new subsets of mantle cell lymphoma. Leuk Lymphoma. 2008;49:1042–9.

    Article  PubMed  CAS  Google Scholar 

  25. Orchard J, Garand R, Davis Z, et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood. 2003;101:4975–81.

    Article  PubMed  CAS  Google Scholar 

  26. Camacho FI, Algara P, Rodriguez A, et al. Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations. Blood. 2003;101:4042–6.

    Article  PubMed  CAS  Google Scholar 

  27. Parry-Jones N, Matutes E, Morilla R, et al. Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH. Br J Haematol. 2007;137:117–24.

    Article  PubMed  CAS  Google Scholar 

  28. de Vries A, Flores ER, Miranda B, et al. Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci USA. 2002;99:2948–53.

    Article  PubMed  Google Scholar 

  29. Sander S, Bullinger L, Leupolt E, et al. Genomic aberrations in mantle cell lymphoma detected by interphase fluorescence in situ hybridization. Incidence and clinicopathological correlations. Haematologica. 2008;93:680–7.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This study was supported by National Natural Science Foundation of China (30871104, 30971296, and 81170488), Natural Science Foundation of Jiangsu Province (BK2010584), “Qing Lan” project of Jiangsu Province, “Liu Da Ren Cai Gao Feng” of Jiangsu Province. University Doctoral Foundation of the Ministry of Education of China (20093234110010), the Program for Development of Innovative Research Team in the First Affiliated Hospital of NJMU, and Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions.

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China

    Hua-Jie Dong, Li-Tao Zhou, Cheng Fang, Lei Fan, Dan-Xia Zhu, Yin-Hua Wang, Jian-Yong Li & Wei Xu

  2. Department of Oncology, Changzhou Cancer Hospital of Soochow University, Changzhou, 213002, China

    Hua-Jie Dong

  3. Department of Hematology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, 223300, China

    Li-Tao Zhou

Authors
  1. Hua-Jie Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Li-Tao Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Cheng Fang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lei Fan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dan-Xia Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yin-Hua Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jian-Yong Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Wei Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wei Xu.

Additional information

Hua-Jie Dong and Li-Tao ZHOU are contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Dong, HJ., Zhou, LT., Fang, C. et al. TP53 mutation is not an independent prognostic factor in patients with mantle cell lymphoma at advanced stage. Med Oncol 29, 2166–2173 (2012). https://doi.org/10.1007/s12032-011-0096-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-011-0096-5

Keywords

Search

Navigation